AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
05. April 2023 08:00 ET
|
AI Therapeutics, Inc.
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed the blood-brain barrier ...
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS
13. Januar 2022 10:38 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...